Efficacy and Safety of a Combined Serum Containing Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES

NANot yet recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

November 28, 2025

Study Completion Date

December 1, 2025

Conditions
MelasmaPost-acne Hyperpigmentation
Interventions
DRUG

a combination serum containing Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES

Subjects were randomized to receive a combination serum The combination serum contained Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES. applied twice daily, following QS-Nd:YAG 1064 nm low-fluence laser treatment. Clinical evaluations were conducted at baseline and at Weeks 1, 2, and 4 post-laser to assess pigmentation improvement, erythema, and overall skin condition.

DRUG

2% hydroquinone cream

Subjects were randomized to received 2% hydroquinone cream, applied once daily at night, following QS-Nd:YAG 1064 nm low-fluence laser treatment. Clinical evaluations were conducted at baseline and at Weeks 1, 2, and 4 post-laser to assess pigmentation improvement, erythema, and overall skin condition.

Trial Locations (1)

10410

Gatot Soebroto Central Army Hospital, Jakarta Pusat

All Listed Sponsors
lead

Dr.dr.Irma Bernadette, SpKK (K)

OTHER

NCT07121439 - Efficacy and Safety of a Combined Serum Containing Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES | Biotech Hunter | Biotech Hunter